1. Introduction {#sec1}
===============

Osteoporosis (OP) is a disease characterized by low bone mineral density (BMD) and a high risk of fractures \[[@B1]\], with clinical manifestations of pain, muscle weakness, and fractures \[[@B2]\]. Approximately 9 million people worldwide suffer from OP or fragility (low trauma) fractures each year \[[@B3]\]. Previous studies have found that acupuncture could significantly increase the BMD of lumbar vertebrae, the values of trabecular area, and trabecular bone number, as well as reducing trabecular separation in postmenopausal OP rats \[[@B4]\]. Similar but slightly different results occur simultaneously in patients with OP \[[@B5]\]. In recent years, the number of patients seeking complementary and alternative therapies, including acupuncture, has grown continuously in clinical practice \[[@B6]\], leading to a large number of clinical trials and meta-analyses related to acupuncture for OP being published in various journals and databases \[[@B5], [@B7]\]. However, these studies are influenced by a series of biases and increasingly include nonrandomized clinical trials \[[@B8]\]. Identifying quality evidence and potential treatment strategies from these studies and applying it to clinical practice still remains a challenge for clinicians \[[@B9], [@B10]\]. Therefore, identifying clinical evidence and exploring treatment strategies of acupuncture has become an urgent problem.

The Veritas plot is a graphic tool adapted from radar plots to describe multiattribute data \[[@B10]\]. This technique was first applied to identify the highest quality meta-analytical literature of cardiac surgery \[[@B10]\]. As an evidence-synthesis graphic tool, Veritas plots are now widely used to identify and interpret variability in meta-analyses and to help clinicians use the highest quality evidence of acupuncture in clinical practice \[[@B11]\]. However, Veritas plots have not been applied to acupuncture for primary OP. TCMISS is a data mining tool invented by the*Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences* for exploring potential treatment strategies of acupuncture or Chinese medicine \[[@B12], [@B13]\]. It includes different functions such as text mining, association rules analysis, and complex system entropy methods, making it easy and convenient for researchers without algorithmic experience to use it for data mining \[[@B14]\]. It can be used to guide clinicians in selecting appropriate acupoints or Chinese herbs to treat specific diseases \[[@B14], [@B15]\]. However, data mining has not been conducted to explore potential acupuncture prescriptions for primary OP.

Given the uncertainty about the quality of meta-analyses and the treatment strategy of acupuncture for OP, we used Veritas plots to assess quality evidence of acupuncture and used TCMISS to explore potential treatment strategies of acupuncture for primary OP. In addition, we summarized the major antiosteoporotic effects and potential mechanisms of core acupoints identified by data mining. These will help clinicians establish a specific acupuncture prescription for OP and use it in clinical practice.

2. Methods {#sec2}
==========

2.1. Participants {#sec2.1}
-----------------

Patients with primary OP were included as participants in this study. The diagnostic criteria for primary OP were based on the 1999 World Health Organization criteria: BMD is measured by dual energy X-ray absorptiometry as a T-score below -2.5 standard deviations (SD) in the femur neck, lumbar spine, or total femur region \[[@B16]\]. There were no restrictions on age, sex, race, language, or region.

2.2. Selection Criteria {#sec2.2}
-----------------------

This study included randomized control trials (RCTs) and/or clinical control trials (CCTs) and systematic reviews and/or meta-analyses of acupuncture for OP. Cross-sectional studies, comments, cohort studies, animal experiments, and reviews were excluded.

2.3. Search Strategy {#sec2.3}
--------------------

A systematic electronic search was conducted of CBM, VIP Database, Wanfang Data, CNKI, PubMed, Springer, Cochrane Library, and Embase for relevant RCTs and/or CCTs and systematic reviews and/or meta-analyses. All of the databases were searched from their inception to October 31, 2018. The search algorithm for PubMed was as follows: ("acupuncture" or "electroacupuncture" or "needle warming therapy" or "eye acupuncture" or "foot acupuncture" or "wrist-ankle acupuncture" or "hand acupuncture" or "hand-foot acupuncture" or "face acupuncture" or "nose acupuncture" or "Ashi points") and ("age-related osteoporosis" or "senile osteoporosis" or "postmenopausal osteoporosis" or "primary osteoporosis") and ("randomized controlled trial" or "trial" or "clinical trial" or "systematic review" or "meta-analysis"), with no restriction on subheadings. Similar but adapted search terms were used in other databases. Clinical trials published in abstract form were excluded unless sufficient information could be obtained from the abstract or authors. Reference lists of the retrieved papers were also reviewed to discover other studies, and studies not included in the databases mentioned previously were additionally searched.

2.4. Data Selection {#sec2.4}
-------------------

The results from different databases were imported into NoteExpress 3.2.0 (<http://www.inoteexpress.com/aegean/>). Duplicate studies were then identified and deleted with NoteExpress 3.2.0. Two authors conducted data selection independently (Lin HX and Wang XT), reviewed the abstracts and full texts, and extracted the relevant information from the included studies. Any discrepancies were resolved by consensus.

2.5. Data Extraction {#sec2.5}
--------------------

Two reviewers (Wang XT and Lin HX) extracted study information for each eligible study, including the first author names, publication year, data sources, time range for inclusion in the study, detailed search strategies, search process, sample sizes, number of patients, bias assessment tools, outcomes, and methods of reporting publication bias. Data was checked by Yingjie Mo.

2.6. Veritas Score Indicators {#sec2.6}
-----------------------------

Veritas scores were determined for publication year, study type, Assessment of Multiple Systematic Reviews (AMSTAR) 2 score, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) score, heterogeneity, and publication bias to assess the quality of included systematic reviews or meta-analyses. The year a study was published was an important factor of heterogeneity, as disease and acupuncture techniques may change over time, whereas technical expertise may have led to unfavorable results in early studies \[[@B17]\]. The AMSTAR 2, updated in 2017, could provide readers with a better summary assessment to determine whether the systematic review has met the methodological safeguards against bias \[[@B18]\]. PRISMA statement could accurately reflect the ability of researchers to write in a comprehensible manner, instead of the way they conducted the review \[[@B19], [@B20]\]. Heterogeneity in study design or intervention has a significant impact on the conduct and outcomes of a meta-analysis \[[@B21]\] and often affects acupuncturists in some important decisions, such as whether a treatment is applicable to all targeted people \[[@B22]\]. Publication bias is an inherent problem in meta-analyses because some studies are not published in indexed journals, and some negative results were not publicly available \[[@B23], [@B24]\].

2.7. Ranking of Evidence {#sec2.7}
------------------------

The meta-analyses were ranked according to six categories: year of publication, study type, AMSTAR2 score, PRISMA score, heterogeneity, and publication bias. For publication year, if the publication year of multiple studies was the same, we ranked studies by the time range for inclusion in the study. In the AMSTAR 2 score, if the study meets the criteria of AMSTAR 2 item, it scores 1 point in this item; 0.5 points for those that partially satisfy the criteria; otherwise 0 points. In the PRISMA score, 2 points were given for studies that completely meet the criteria of the PRISMA item; 1 point for those that partially satisfy the criteria; otherwise 0 points. The heterogeneity score is the average of the heterogeneity scores for clinical outcomes. Heterogeneity among studies was calculated using the chi-square test and I^2^ statistic \[[@B25]\]. 0% ≤ I^2^ ≤ 50% indicated no heterogeneity and the score is 3 points, 50% \< I^2^ ≤ 75% was considered slightly significant heterogeneity and scores 2 points, and I^2^ \> 75% was regarded as significant heterogeneity and scores 1 point.

The scoring system was applied as follows \[[@B10]\]: in each category, the best study got the highest score of n, where n = the number of studies. The second best study got n-1 points, and so on. If two studies performed equally well, the included study with the next highest score would get n-2 points. We considered the Veritas score as a summary statistic. The Veritas score of each study is the average scores in the six dimensions of quality.

2.8. Data Mining Analysis {#sec2.8}
-------------------------

Data were analyzed by TCMISS Version 2.5 (*invented by Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences*). We first analyzed the frequency of acupoints, meridians, and common acupoint combinations using text mining. Then we conducted an association rule analysis to determine the support value of different acupoints and the core acupoints association network of acupuncture for primary OP. We set the "the degree of support" to 60, which means the frequency of A and B appearing at the same time is 60. The "confidence level" was set to 0.6, which means that when A occurs, the probability of B appearing is 60%. We also further analyzed the cooccurrence matrix of the top 23 acupoints using Heml 1.0.3.7 (<http://hemi.biocuckoo.org/down.php>). The results were represented by a heat map.

2.9. Summary of Major Antiosteoporotic Effects and Potential Mechanisms of Core Acupoints {#sec2.9}
-----------------------------------------------------------------------------------------

The major antiosteoporotic effects and underlying mechanisms of core acupoints identified by data mining were summarized using published studies, thereby providing evidence for the patients and acupuncturists of the applications of acupuncture for primary OP

3. Results {#sec3}
==========

3.1. Eligible Studies {#sec3.1}
---------------------

The research process is summarized in [Figure 1](#fig1){ref-type="fig"}. We firstly identified 2204 citations through an initial search and identified 821 potential articles after removing duplicated records. After screening the titles and abstracts, 558 studies were deleted. We included 228 studies after screening the full text of these 558 studies. In total, 218 studies were clinical trials and the acupoint characteristics were analyzed using TCMISS Version 2.5. Ten studies were meta-analyses and the evidence was ranked using Veritas scores. The baseline characteristics of the meta-analyses are presented in [Table 1](#tab1){ref-type="table"}. The meta-analyses were published between 2014 and 2018, with data from 12 databases including Embase, Medline, the Cochrane Library, ScienceDirect, PubMed, AMED, CBM, VIP Database, Wanfang Data, CNKI, Web of Science, and The Cochrane Central Register of Controlled Trials. The databases were searched from their inception to October 31, 2018, in the latest meta-analysis. A total of 138 clinical trials involving 11,232 patients were included in 10 meta-analyses. Five meta-analyses provided a detailed search strategy. Six meta-analyses had search processes that were performed independently by two reviewers. In the bias assessment, five meta-analyses used Cochrane Collaboration\'s risk of bias tool, while others used the Jadad scale. Four meta-analyses did not report publication bias.

3.2. Veritas Score {#sec3.2}
------------------

The scores of included meta-analyses are presented in [Table 2](#tab2){ref-type="table"}. The detailed heterogeneity score, AMSTAR 2 score, and PRISMA score of included studies are shown in Supplementary Tables [1](#supplementary-material-1){ref-type="supplementary-material"}, [2](#supplementary-material-1){ref-type="supplementary-material"}, and [3](#supplementary-material-1){ref-type="supplementary-material"}, respectively. We also developed summary Veritas plots of the 10 studies ([Figure 2](#fig2){ref-type="fig"}). The mean Veritas scores of publication year, type of study, AMSTAR 2 score, PRISMA score, heterogeneity, and publication bias, were 5.5, 7.2, 6, 5.6, 5.8, and 7.5, respectively. The number of meta-analyses that exceeded the mean Veritas scores of publication year, type of study, AMSTAR 2 score, PRISMA score, heterogeneity, and publication bias was 5, 6, 5, 6, 5, and 5, respectively. The study with the highest Veritas score was by Pan et al. (2018), with 8.67 points, while the lowest Veritas score was Li et al. (2014), with 4 points. There were 5 studies with Veritas scores ≥ 6.27 points. In [Figure 3](#fig3){ref-type="fig"}, the individual Veritas scores for all of the meta-analyses are plotted.

3.3. Frequency Statistics of Acupoints {#sec3.3}
--------------------------------------

A total of 212 acupuncture prescriptions were included, which involved 102 acupoints. The top 30 acupoints of acupuncture for OP are presented in [Table 3](#tab3){ref-type="table"}. Acupoints BL23, BL20, ST36, and GV4 were used in more than 60% of the acupuncture prescriptions, with frequency of 178, 120, 112, and 111, respectively. There were 10 acupoints with frequency ≥ 50, which were BL23, BL20, ST36, GV4, SP6, CV4, KI3, GV3, BL40, and BL11.

3.4. Frequency Statistics of Meridians {#sec3.4}
--------------------------------------

Meridians and acupoints used in acupuncture therapy for primary OP are shown in [Table 4](#tab4){ref-type="table"}. A total of 13 meridians, three extra meridians, and one Ashi point were used in acupuncture for primary OP. There were six meridians used over 100 times, including stomach meridian of foot-yangming (ST), spleen meridian of foot-taiyin (SP), governor vessel (GV), gallbladder meridian of foot-shaoyang (GB), conception vessel (CV), and bladder meridian of foot-taiyang (BL). The most frequently used meridian was BL, which was used 640 times and involved 31 acupoints. The second most commonly used meridian was GV, which was used 269 times and involved 13 acupoints. CV was the third most frequently used meridian, with 147 times and nine points.

3.5. Common Acupoint Combinations {#sec3.5}
---------------------------------

The common acupoint combinations of acupuncture for primary OP are presented in [Table 5](#tab5){ref-type="table"}. A total of 15 common acupoint combinations were frequently used over 60 times. There were three acupoint combinations with frequency ≥ 100: BL23 and BL20, BL23 and GV4, and BL23 and ST36. The acupoint combination BL23 and BL20 was used 117 times in acupuncture therapy for OP, accounting for about 50% of acupuncture prescriptions. The second most frequently used acupoint combination was BL23 and GV4, with 104 times. Acupoints BL20 combined with ST36 and BL23, BL20 combined with ST36 were used as many as 76 times. These results were consistent with the cooccurrence matrix of acupoints, which are shown in [Figure 4](#fig4){ref-type="fig"}. There were 18 pairs of acupoints with a cooccurrence frequency above 50, of which four pairs were above 75.

3.6. Association Rules of Acupoints {#sec3.6}
-----------------------------------

We present the association rules for acupoints in [Table 6](#tab6){ref-type="table"}. There were 22 acupoint combinations with confidence levels ranging from 60% to 98.7%, seven of which were above 90%, such as acupoint BL20, ST36 -\> BL23; BL20 -\> BL23; CV4 -\> BL23; BL20, GV4 -\> BL23; SP6 -\> BL23; GV4 -\> BL23; KI3 -\> BL23. The acupoint combinations of BL20 and ST36 with BL23 have the highest confidence level of 98.7%, which means that when BL20 and ST36 were selected, the probability of selecting BL23 was 98.7%. The acupoint combination of BL20 and BL23 has the second highest confidence level of 97.5%. The core acupoints association network of acupuncture for primary OP is shown in [Figure 5](#fig5){ref-type="fig"}, including acupoints BL23, BL20, ST36, GV4, SP6, CV4, and KI3. The degree of support from strong to weak was acupoint BL23 combined with BL20, BL23 with ST36, BL23 with GV4, BL20 with ST36, BL23 with SP6, BL23 with KI3, ST36 with GV4, ST36 with SP6, BL23 with CV4, and SP6 with BL20.

3.7. Beneficial Effects of Core Acupoints on Primary OP and Potential Mechanisms {#sec3.7}
--------------------------------------------------------------------------------

Representative examples of major antiosteoporotic effects of core acupoints and potential mechanisms are presented in [Table 7](#tab7){ref-type="table"}. The prevention of primary OP in acupoints BL23 and BL20 was mainly to reduce the loss of bone mass, increase femoral BMD, and improve the microstructure of bone tissue. The role of acupoints ST36, SP6, CV4, and KI3 in preventing OP was mainly to increase E~2~ levels and BMD. The antiosteoporotic effects of acupoints GV4 and CV4 were to reduce the loss of bone mass and increase the femoral BMD. The potential antiosteoporotic mechanisms in acupoints BL23, BL20, and GV4 were to upregulate the ratio of OPG/RANKL, and LRP5, *β*-catenin, and Runx2 expression. In addition, acupoints BL23 and BL20 also could downregulate the expression of phosphorylated (p)-p38 and p-JNK. The potential antiosteoporosis mechanism in acupoints SP6 and KI3 was to decrease the concentration of TNF*α* and IgM. Acupoint ST36 could reduce OPGL expression and upregulate the expression levels of RANKL mRNA. Acupoint CV4 could upregulate the expression levels of ER-*α* and ERA-*α* mRNA in uterus, hypothalamus, and spleen.

4. Discussion {#sec4}
=============

In our study, we presented a novel application of Veritas plots that acupuncturists can use to evaluate key attributes of meta-analysis quality without extensive narratives. A total of 10 meta-analyses were included. The mean Veritas score of publication year, type of study, AMSTAR 2, PRISMA, heterogeneity, and publication bias were 5.5, 7.2, 6, 5.6, 5.8, and 7.5, respectively, indicating that the included meta-analyses performed well in the following areas: timely update results, high consistency of study type, compliance with PRISMA statements, and low heterogeneity. However, the statement of the review method, the assessment of the potential impact of risk of bias in individual studies on the results, the list of excluded studies, funding sources, and conflicts of interest in AMSTAR 2 were insufficient. Some meta-analyses did not assess publication bias, indicating that we should pay more attention to the methodological guarantee of bias, and consider the clinical value of the results carefully. A similar phenomenon also occurs in acupuncture treatment of anxiety disorders \[[@B42]\], which indicates a direction to further improve the quality of research. With the help of the Veritas scores, we ultimately found that the study of Pan et al. \[[@B26]\] performed well in the year of publication, type of study, AMSTAR 2 score, PRISMA score, and publication bias and received the highest Veritas score of 8.67 points.

In this study, we used TCMISS to investigate the meridians, acupoint combinations, and core acupoints for primary OP. A total of 212 acupuncture prescriptions were included, including 102 acupoints, 13 meridians, three extra meridians, and one Ashi point. The most frequently used meridian was BL, which was used 640 times and involved 31 acupoints. The second most frequently used meridian was GV. Experiments in ovariectomized rats have demonstrated that acupuncture at BL and GV acupoints could alleviate osteoporosis by regulating the OPG/RANKL and Wnt/beta-catenin signaling pathways \[[@B38]\]. Acupoint combination BL23 and BL20 was used in about 50% of acupuncture prescriptions, with a frequency of 117. The second most frequent acupoint combination was BL23 and GV4, and the third was BL23 and ST36. A clinical study has demonstrated that electroacupuncture stimulation at BL20/BL23 could increase levels of osteocalcin and the BMD of lumbar vertebrae, as well as improving bone microstructure in the femur \[[@B4]\]. The core acupoints association network of acupuncture for primary OP included BL23, BL20, ST36, GV4, SP6, CV4, and KI3. BL23 and KI3 \[[@B6]\] and BL23 and GV4 \[[@B43]\] have been demonstrated in randomized controlled trials to improve quality of life and reduce pain in patients with primary OP. At the same time, we summarized the major antiosteoporotic effects and potential mechanisms of core acupoints based on published studies. The major antiosteoporotic effects of core acupoints were increased BMD and reduced loss of bone mass. The underlying antiosteoporotic mechanisms were to upregulate the expression of members in OPG/RANKL, Wnt/*β*-catenin, and MAPK pathways, such as LRP5, *β*-catenin, Runx2, and OPG.

5. Limitations {#sec5}
==============

There are some limitations in this study. First, we did not assess the impact of population factor on the results, which is different from the Panesar et al. study \[[@B10]\]. Second, the number of clinical trials, especially the multicenter randomized controlled clinical trials that validated the experience of well-known Chinese medicine practitioners, is small. This may limit the applications of the results. Third, the acupoint combinations and core acupoints of acupuncture for primary OP were rarely confirmed by large-scale multicenter clinical trials or animal experiments.

6. Conclusion {#sec6}
=============

Our Veritas plots enable acupuncturists to evaluate key attributes of meta-analysis quality related to acupuncture for primary OP and to improve the quality of evidence-based medicine related to acupuncture. Data mining analysis revealed an associated network involving meridians, acupoint combinations, core acupoints, and the underlying mechanisms of acupuncture for primary OP. Future large-sample multicenter RCTs and animal experiments should be conducted to confirm our findings.
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Additional Table 1: heterogeneity score of included studies. Additional Table 2: the Assessment of Multiple Systematic Reviews (AMSTAR) 2 tool. Additional Table 3: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 Checklist.
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![*Flow chart of the research process*. CBM = Chinese Biomedical Medicine, CNKI = China National Knowledge Infrastructure, AMSTAR = Assessment of Multiple Systematic Reviews tool, and PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](ECAM2019-2705263.001){#fig1}

![*Veritas plots for included studies*. AMSTAR = Assessment of Multiple Systematic Reviews tool; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](ECAM2019-2705263.002){#fig2}

![*Comparison of Veritas score in all included studies*. AMSTAR = Assessment of Multiple Systematic Reviews tool; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](ECAM2019-2705263.003){#fig3}

![Cooccurrence matrix of acupoints.](ECAM2019-2705263.004){#fig4}

![*Core acupoints association network of acupuncture for primary osteoporosis*. The size of the circle represents the frequency and the width of the line indicates the degree of support.](ECAM2019-2705263.005){#fig5}

###### 

Baseline characteristics of studies included in our example.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies                                Data Sources                                                                                                       Time                       Detailed search strategy   Search process                Number of studies   Number of patients\   Bias assessment tool                          Outcomes                                                                                                    Report publication bias
                                                                                                                                                                                                                                                                    (E/C)                                                                                                                                                                           
  -------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------------------------- -------------------------- ----------------------------- ------------------- --------------------- --------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------
  Hong Pan et al. 2018 \[[@B26]\]        Embase, Medline, the Cochrane library, ScicenceDirect, PubMed, AMED, CBM, Wanfang, CNKI, VIP                       Before April 2017          Yes                        Two reviewers independently   35                  1517/1465^*∗*^        Cochrane Collaboration\'s risk of bias tool   clinical therapeutic effect, BMD, Pain VAS, Serum Calcium, Serum Alkaline Phosphatase, E2                   Funnel plot

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Jinfeng Chen et al. 2018 \[[@B27]\]    PubMed, CNKI, CBM, VIP, Wanfang                                                                                    Before November 2016       Yes                        Not mention                   12                  515/481               Jadad Scale                                   clinical therapeutic effect, BMD, Pain scale, BGP, Serum Alkaline Phosphatase, safety                       Funnel plot

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Ding Luo et al. 2018 \[[@B5]\]         Medline, Embase, Cochrane Library, Web of Science, CNKI, the Chinese VIP database and Wangfang database            Before June 30, 2016       Yes                        Two reviewers independently   9                   303/269^*∗*^          Cochrane Collaboration\'s risk of bias tool   BMD of lumbar vertebrae, BMD of femoral neck, Ward\'s triangle and greater Trochanter, pain VAS             None

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Xiaotong Wang et al. 2018 \[[@B28]\]   CNKI, Wanfang, CBM, VIP, PubMed                                                                                    Before June 1, 2016        Yes                        Two reviewers independently   4                   93/93                 Cochrane Collaboration\'s risk of bias tool   clinical therapeutic effect, BMD, E2, BGP, Ca/Cr                                                            None

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Ding Luo et al. 2017 \[[@B29]\]        CNKI, Wanfang, VIP, PubMed, Embase, The Cochrane Central Register of Controlled Trials                             Before October 1, 2016     None                       Not mention                   23                  959/917^*∗*^          Cochrane Collaboration\'s risk of bias tool   clinical therapeutic effect, Pain scale, BMD of lumbar vertebra, E2, testosterone, BGP, TCM symptom score   Funnel plot, Egger\'s test

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Yanan Wu et al. 2017 \[[@B30]\]        CNKI, Wanfang, VIP, PubMed, EMBASE, The Cochrane Central Register of Controlled Trials                             Before December 1, 2015    None                       Two reviewers independently   11                  487/485               Cochrane Collaboration\'s risk of bias tool   Pain scale, BMD of lumbar vertebra, TCM symptom score, effectiveness                                        Funnel plot, Egger\'s test

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Li Xiao et al. 2016 \[[@B31]\]         CNKI, VIP, Wanfang, CBM, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase                  2006.1-2016.7              None                       Two reviewers independently   10                  477/476^*∗*^          Jadad Scale                                   clinical therapeutic effect, E2, BMD                                                                        Funnel plot

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Longyun Zhou et al. 2016 \[[@B32]\]    CNKI, VIP, CBM, Wanfang, Chinese Clinical Trial Registry, PubMed, Cochrane Library, Web of Science, Embase, AMED   Before September 1, 2015   Yes                        Two reviewers independently   16                  658/606               Jadad Scale                                   clinical therapeutic effect, Pain measurement, BMD, safety                                                  Funnel plot

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Sheng Li et al. 2014 \[[@B33]\]        CNKI, VIP, Wanfang, CBM, and Luzhou Medical College Library                                                        Before October 1, 2013     None                       Not mention                   9                   365/322               Jadad Scale                                   clinical therapeutic effect, BMD, E2                                                                        None

                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Juntao Xu et al. 2014 \[[@B34]\]       CNKI, VIP, Wanfang                                                                                                 2003-2011                  None                       Not mention                   9                   373/371               Jadad Scale                                   clinical therapeutic effect, bone pain, BMD of lumbar vertebra                                              None
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note*. RCT, randomized control trials; CCT, clinical control trial; BMD, Bone Mineral Density; BGP, bone Gla protein; VAS, visual analog scale; E2, estradiol; TCM, traditional Chinese Medicine; E, experimental group; C, control group; CBM, Chinese Biomedical Medicine; CNKI, China National Knowledge Infrastructure.

*∗*The data is erroneous in the included studies. We have corrected it.

###### 

Scores of included studies.

  Studies                                Studies characteristics (score)   Veritas score                                                                                                             
  -------------------------------------- --------------------------------- --------------- ------------------ -------- ------ -------- ------ -------- ------ -------- -------------------- -------- ------
  Hong Pan et al. 2018 \[[@B26]\]        2018                              \(10\)          RCT                \(10\)   11     \(9\)    47     \(10\)   1.64   \(3\)    Partially assessed   \(10\)   8.67
                                                                                                                                                                                                     
  Jinfeng Chen et al. 2018 \[[@B27]\]    2018                              \(9\)           RCT                \(10\)   9      \(5\)    41     \(6\)    1.4    \(1\)    Partially assessed   \(10\)   6.83
                                                                                                                                                                                                     
  Ding Luo et al. 2018 \[[@B5]\]         2018                              \(8\)           RCT                \(10\)   11.5   \(10\)   46     \(9\)    2.2    \(6\)    None                 \(5\)    8
                                                                                                                                                                                                     
  Xiaotong Wang et al. 2018 \[[@B28]\]   2018                              \(7\)           RCT or CCT         \(2\)    9      \(5\)    42     \(7\)    3      \(10\)   None                 \(5\)    6
                                                                                                                                                                                                     
  Ding Luo et al. 2017 \[[@B29]\]        2017                              \(6\)           RCT                \(10\)   8      \(3\)    36     \(3\)    1.75   \(4\)    Partially assessed   \(10\)   6
                                                                                                                                                                                                     
  Yanan Wu et al. 2017 \[[@B30]\]        2017                              \(5\)           RCT or quasi-RCT   \(4\)    9.5    \(8\)    41     \(6\)    1.5    \(2\)    Partially assessed   \(10\)   5.83
                                                                                                                                                                                                     
  Li Xiao et al. 2016 \[[@B31]\]         2016                              \(4\)           RCT or CCT         \(2\)    9.5    \(8\)    39     \(4\)    3      \(10\)   Partially assessed   \(10\)   6.33
                                                                                                                                                                                                     
  Longyun Zhou et al. 2016 \[[@B32]\]    2016                              \(3\)           RCT                \(10\)   9.5    \(8\)    44     \(8\)    2      \(5\)    None                 \(5\)    6.5
                                                                                                                                                                                                     
  Sheng Li et al. 2014 \[[@B33]\]        2014                              \(2\)           RCT or quasi-RCT   \(4\)    7.5    \(1\)    35     \(2\)    3      \(10\)   None                 \(5\)    4
                                                                                                                                                                                                     
  Juntao Xu et al. 2014 \[[@B34]\]       2014                              \(1\)           RCT                \(10\)   8      \(3\)    25     \(1\)    2.33   \(7\)    None                 \(5\)    4.5
                                                                                                                                                                                                     
  Mean Veritas score                     5.5                               7.2             6                  5.6      5.8    7.5      6.27                                                          

*Note*. AMSTAR = Assessment of Multiple Systematic Reviews tool; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

###### 

Top 30 acupoints of acupuncture for primary osteoporosis.

  Number   acupoints   Frequency   Number   acupoints   Frequency   Number   acupoints   Frequency
  -------- ----------- ----------- -------- ----------- ----------- -------- ----------- -----------
  1        BL23        178         11       GV14        49          21       SP10        19
  2        BL20        120         12       GB39        49          22       CV12        19
  3        ST36        112         13       GB34        46          23       BL17        19
  4        GV4         111         14       Ashi        46          24       BL21        18
  5        SP6         77          15       BL18        44          25       BL52        17
  6        CV4         77          16       BL25        41          26       BL32        16
  7        KI3         76          17       EX-B2       37          27       BL54        16
  8        GV3         60          18       CV6         31          28       GV9         12
  9        BL40        59          19       GB30        21          29       CV8         12
  10       BL11        53          20       GV20        20          30       BL26        11

###### 

Meridians and acupoints used in acupuncture therapy for primary osteoporosis.

  Meridian                                          Times   Number   Acupoints
  ------------------------------------------------- ------- -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bladder meridian of foot-taiyang (BL)             640     31       BL11(53), BL12(2), BL13(3), BL14(1), BL15(1), BL16(1), BL17(19), BL18(44), BL19(1), BL20(120), BL21(18), BL22(1), BL23(178), BL24(7), BL25(41), BL26(11), BL27(1), BL28(1), BL31(8), BL32(16), BL33(1), BL34(1), BL36(9), BL37(1), BL40(59), BL43(1), BL52(17), BL54(16), BL57(5), BL60(2), BL67(1)
  Governor vessel (GV)                              269     13       GV1(1), GV2(3), GV3(60), GV4(111), GV5(2), GV6(2), GV8(1), GV9(12), GV11(2), GV12(2), GV14(49), GV16(4), GV20(20)
  Conception vessel (CV)                            147     9        CV4(77), CV6(31), CV8(12), CV9(2), CV10(3), CV11(1), CV12(19), CV13(1), CV17(1)
  Gallbladder meridian of foot-shaoyang (GB)        135     7        GB20(5), GB21(3), GB30(21), GB31(10), GB34(46), GB35(1), GB39(49)
  Stomach meridian of foot-yangming (ST)            131     6        ST24(4), ST25(6), ST26(3), ST31(2), ST34(4), ST36(112)
  Spleen meridian of foot-taiyin (SP)               114     5        SP3(5), SP6(77), SP9(7), SP10(19), SP15(6)
  Kidney meridian of foot-shaoyin (KI)              89      8        KI1(2), KI3(76), KI4(2), KI7(2), KI10(3), KI13(2), KI14(1), KI16(1)
  Ashi point                                        46      1        Ashi(46)
  Points of back (EX-B)                             40      2        EX-B2(37), EX-B5(3)
  Liver meridian of foot-jueyin (LR)                10      3        LR3(8), LR8(1), LR14(1)
  Large intestine meridian of hand-yangming (LI)    10      4        LI4(4), LI11(3), LI13(1), LI15(2)
  Lung meridian of hand-taiyin (LU)                 6       3        LU5(3), LU7(2), LU9(1)
  Small intestine meridian of hand-taiyang (SI)     5       4        SI3(1), SI9(1), SI11(2), SI15(1)
  Pericardium meridian of hand-jueyin (PC)          4       1        PC6(4)
  Points of chest and abdomen (EX-CA)               3       1        EX-CA1(3)
  Triple energizer meridian of hand-shaoyang (TE)   2       2        TE5(1), TE14(1)
  Points of upper extremities (EX-UE)               1       1        EX-UE1(1)
  Points of lower extremities (EX-LE)               1       1        EX-LE3(1)

###### 

Common acupoint group of acupuncture for primary osteoporosis.

  No.   Acupoint group     Frequency   No.   Acupoint group    Frequency   No.   Acupoint group    Frequency
  ----- ------------------ ----------- ----- ----------------- ----------- ----- ----------------- -----------
  1     BL23, BL20         117         6     BL20, GV4         74          11    ST36, SP6         66
  2     BL23, GV4          104         7     BL23, SP6         72          12    BL23, CV4         66
  3     BL23, ST36         101         8     BL23, BL20, GV4   72          13    ST36, SP6, BL23   62
  4     BL20, ST36         76          9     BL23, KI3         69          14    SP6, BL20         60
  5     BL23, BL20, ST36   76          10    ST36, GV4         62          15    SP6, BL23, BL20   60

###### 

Association rules of acupoints.

  Nio   Acupoints             Confidence level/%   Number   Acupoints             Confidence level/%   Number   Acupoints             Confidence level/%
  ----- --------------------- -------------------- -------- --------------------- -------------------- -------- --------------------- --------------------
  1     BL20, ST36 -\> BL23   98.7                 9        CV4 -\> BL23          86.8                 17       BL23, BL20 -\> ST36   64.1
  2     BL20 -\> BL23         97.5                 10       ST36, BL23 -\> BL20   74.3                 18       BL20 -\> ST36         63.3
  3     BL20, GV4 -\> BL23    97.3                 11       BL23, GV4 -\> BL20    69.2                 19       BL20 -\> ST36, BL23   62.5
  4     SP6 -\> BL23          94.7                 12       ST36 -\> BL20         67.9                 20       BL20 -\> GV4          61.7
  5     GV4 -\> BL23          93.7                 13       ST36 -\> BL23, BL20   67.0                 21       BL23, BL20 -\> GV4    61.5
  6     KI3 -\> BL23          90.8                 14       GV4 -\> BL20          66.7                 22       BL20 -\> BL23, GV4    60.0
  7     ST36 -\> BL23         90.7                 15       BL23 -\> BL20         66.5                                                 
  8     SP6 -\> ST36          86.8                 16       GV4 -\> BL23, BL20    64.9                                                 

###### 

Representative examples of major antiosteoporotic effects of core acupoints and potential mechanisms.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Acupoints   Beneficial Effects                                                                                                                                                                                                                                               Potential Mechanisms                                                                                                                            Experimental Models Used   Ref. \#
  ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- --------------------
  BL23        reduce the loss of bone mass, increase femoral BMD, improve the microstructure of bone tissue, promote bone formation, restore the amount of bone volume, improve bone architecture, enhance the secretion of testosterone                                       Upregulate the ratio of OPG/RANKL and LRP5, *β*-catenin and Runx2 expression; downregulate the expression of phosphorylated (p)-p38 and p-JNK   rodent models              \[[@B4], [@B35]\]

  BL20        reduce the loss of bone mass, increase femoral BMD, improve the microstructure of bone tissue                                                                                                                                                                    Upregulate the ratio of OPG/RANKL and LRP5, *β*-catenin and Runx2 expression; downregulate the expression of phosphorylated (p)-p38 and p-JNK   rodent models              \[[@B4]\]

  ST36        increase the tibia BMD, increased E~2~ levels                                                                                                                                                                                                                    Reduced OPGL expression; upregulate the expression levels of RANKL mRNA                                                                         Rabbits,\                  \[[@B36], [@B37]\]
                                                                                                                                                                                                                                                                                                                                                                                                                               rodent models              

  GV4         reduce the loss of bone mass, increase the femoral BMD, improve the microstructure of the bone tissue                                                                                                                                                            Upregulate the ratio of OPG/RANKL expression; upregulate the expression levels of LRP5, *β*-catenin and Runx2                                   rodent models              \[[@B38]\]

  SP6         increase BMD, increased E~2~ levels                                                                                                                                                                                                                              Decrease the concentration of TNF*α* and IgM                                                                                                    Human body                 \[[@B7]\]

  CV4         increase E~2~ levels, promote the serum ALP level, compress the serum DPD, promote bone formation, decrease the bone absorb, increase the immune function, resist the apoptosis and delay the regressive changes in uterus, strengthen the homeostasis of body   Upregulate the expression levels of ER-*α* and ER-*α* mRNA in uterus, hypothalamus and spleen                                                   rodent models              \[[@B40], [@B41]\]

  KI3         increase BMD, E~2~ levels                                                                                                                                                                                                                                        Decrease the concentration of TNF*α* and IgM                                                                                                    Human body                 \[[@B7]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MD = bone mineral density, JNK = c-Jun N-terminal kinase, OPGL = osteoprotegerin ligand, RANKL = receptor activator of NF-kB ligand, Ig = immunoglobulin, E~2~ = oestradiol, OPG = osteoprotegerin, TNF = tissue necrosis factor, ALP = alkaline phosphatase, DPD = deoxypyridinoline, ER-*α* = estrogen receptor-*α*, LRP = lipoprotein receptor-related protein, Runx = runt-related transcription factor.

[^1]: Academic Editor: Albert S. Yeung
